证券代码：002365 证券简称：永安药业 公告编号：2025-62 潜江永安药业股份有限公司 第七届董事会第十次临时会议决议公告 根据公司经营发展需要，同意聘任董世豪先生为公司副总经理，聘任彭波先 生、吴旭先生、黄宁军先生为公司高级管理人员，任期自本次董事会审议通过之 日起至第七届董事会任期届满之日止。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第十次临时 会议的会议通知于 2025 年 10 月 24 日以书面、电话、传真、电子邮件等形式送 达公司全体董事，会议于 2025 年 10 月 29 日在公司会议室以通讯方式召开，本 次会议应参与审议表决董事 7 人，实际参与审议表决董事 7 人。本次会议由董事 长陈勇先生主持，会议的召集和召开符合《公司法》及《公司章程》的规定。会 议以书面记名投票方式逐项表决，通过了如下决议： 一、审议通过《关于选举第七届董事会副董事长的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 根据《公司章程》相关规定，同意选举董事陈子笛先生为公司第七届董事会 ...

Group 1 - The core viewpoint of the article highlights that Yong'an Pharmaceutical reported a revenue of 210 million yuan in the third quarter, representing a year-on-year increase of 8.75% [1] - The net profit for the third quarter was 13.0005 million yuan, showing a year-on-year growth of 38.75% [1] Group 2 - For the first three quarters, the total revenue was 577 million yuan, which reflects a year-on-year decline of 6.72% [1] - The net profit for the first three quarters was 25.4963 million yuan, indicating a significant year-on-year decrease of 58.78% [1]

Financial Performance - The company's revenue for Q3 2025 was ¥209,771,612.84, representing an increase of 8.75% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2025 was ¥13,000,535.84, a significant increase of 38.75% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,899,082.25, up 91.82% compared to the previous year[5]. - Total operating revenue for the current period was ¥577,148,711.33, a decrease of 6.7% from ¥618,715,718.75 in the previous period[24]. - Net profit for the current period was ¥16,342,120.79, down 72.2% from ¥58,799,695.42 in the previous period[25]. - The profit attributable to the parent company's shareholders was ¥25,496,259.56, a decrease of 58.8% compared to ¥61,855,243.42 in the previous period[25]. - Basic earnings per share for the current period was ¥0.0881, down from ¥0.2105 in the previous period[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,262,430,873.84, a decrease of 2.00% from the end of the previous year[5]. - Total assets decreased to ¥2,262,430,873.84 from ¥2,308,602,905.85, reflecting a decline of 2.0%[23]. - Total liabilities decreased to ¥247,199,813.94 from ¥266,545,677.53, a reduction of 7.3%[23]. - Total equity attributable to the parent company was ¥1,976,432,019.92, down from ¥1,993,780,889.08, a decrease of 0.9%[23]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥98,664,888.88, an increase of 5.76%[5]. - Operating cash flow for the current period is ¥98,664,888.88, an increase of 0.4% compared to ¥93,294,328.83 in the previous period[26]. - Total cash inflow from investment activities decreased to ¥779,294,652.40 from ¥938,272,584.94, a decline of approximately 16.9%[26]. - Net cash flow from investment activities is -¥110,081,416.72, improving from -¥145,855,877.36 in the previous period[26]. - Cash inflow from financing activities decreased to ¥15,000,000.00 from ¥20,600,000.00, a decline of 27.0%[27]. - Net cash flow from financing activities is -¥76,004,051.88, worsening from -¥54,723,270.65 in the previous period[27]. - The net increase in cash and cash equivalents for the current period is -¥85,570,105.23, compared to -¥101,078,767.21 in the previous period[27]. - The ending balance of cash and cash equivalents is ¥234,835,187.73, up from ¥193,149,436.01 in the previous period[27]. - Cash received from the sale of goods and services is ¥604,670,318.15, down 8.2% from ¥658,699,780.62[26]. - Total cash outflow from operating activities is ¥548,206,206.09, a decrease from ¥634,892,089.71, reflecting a reduction of approximately 13.6%[26]. - Cash received from tax refunds is ¥18,198,428.70, down from ¥21,847,313.41, a decline of about 16.1%[26]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 57,923[12]. - The largest shareholder, Chen Yong, holds 21.54% of the shares, amounting to 63,468,000 shares[12]. - The company repurchased 5,537,350 shares, representing 1.88% of the total shares, ranking fourth among all shareholders[13]. - The top ten shareholders include Huanggang Yong'an Pharmaceutical Co., Ltd. with a 2.82% stake, amounting to 8,313,532 shares[12]. - The company completed a share reduction plan where the controlling shareholder reduced their stake by 2,632,300 shares, accounting for 0.8933% of the total share capital[16]. Corporate Actions - The company approved the acquisition of 49.20% equity from minority shareholders of Hubei Ling'an Technology Co., Ltd. for a total of RMB 27 million[15]. - Following the acquisition, the company will hold 100% equity in Ling'an Technology, with no changes to the consolidated financial statement scope[15]. - The company plans to adjust its business scope and increase the board members from 6 to 7, adding one employee representative director and one vice chairman[14]. - The company will abolish the supervisory board, transferring its powers to the audit committee of the board[14]. - The company completed the necessary business registration changes and obtained a new business license on October 21, 2025[14]. Legal and Compliance - The company is actively monitoring the progress of a patent infringement lawsuit in the U.S. where it was previously cleared of any infringement claims[17]. Operational Challenges - The company experienced a 73.63% decrease in operating profit, attributed to a decline in sales volume and price of its main product, taurine[10]. - Sales expenses increased by 167.48% year-on-year, mainly due to increased promotion and advertising costs for the company's self-owned brand products[9]. - The company has reported a significant decrease in cash reserves, which may impact future operational liquidity[21].

Core Viewpoint - The company emphasizes the importance of safety in production as a fundamental principle for its development, especially in light of recent safety incidents in the industry [2]. Group 1 - The company is committed to high-quality development and will implement various measures to strengthen safety foundations and improve operational quality [2]. - The company aims to ensure sustainable and healthy growth in its operations [2].

Group 1 - The core viewpoint of the article is that Yong'an Pharmaceutical's subsidiary, Yong'an Kangjian Yijian, is progressing as planned in expanding its offline channel for self-branded products and is currently in discussions with mainstream chain channels [2] Group 2 - Yong'an Pharmaceutical is actively engaging in communication and negotiation with major retail chain partners to enhance its market presence [2] - The company is focused on a structured approach to advance its product distribution strategy [2]

Core Viewpoint - Yong'an Pharmaceutical reported that as of October 10, 2025, the number of shareholders reached 58,256 [2] Company Summary - Yong'an Pharmaceutical's shareholder count is projected to be 58,256 by October 10, 2025 [2]

Core Viewpoint - The management of Yong'an Pharmaceutical emphasizes the importance of fundamental performance as the core support for stock price, aiming to enhance profitability and intrinsic value as primary tasks [2] Group 1: Business Strategy - The company is focused on strengthening its competitive advantage in the taurine business through market expansion, research and development innovation, cost reduction, efficiency improvement, and management optimization [2] - Yong'an Pharmaceutical plans to diversify by expanding into surrounding products and downstream processing markets related to taurine, aiming to cultivate new growth points for performance [2] Group 2: Management Commitment - The management is committed to improving operational quality and will continue to implement various operational measures to enhance the company's performance [2]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is progressing as planned with its offline channel for self-owned brand products through its subsidiary Yong'an Kangjian Yijian, currently in discussions with mainstream chain channels [1] Group 1 - Yong'an Kangjian Yijian is advancing its offline channel strategy in an orderly manner [1] - The company is in the communication and negotiation phase with major chain channels [1]

Core Points - Yong'an Pharmaceutical announced the convening of the 9th temporary meeting of the 7th Board of Directors on September 24, 2025, and the second temporary shareholders' meeting on October 14, 2025, to review proposals regarding changes in business scope, increasing the number of board members, and amendments to the articles of association [1] - The company has completed the industrial and commercial change registration and the filing of the articles of association, and has obtained a new business license issued by the Hubei Provincial Market Supervision Administration [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-61 潜江永安药业股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 9 月 24 日及 2025 年 10 月 14 日分别召开第七届董事会第九次临时会议及 2025 年第二次临时 股东会，审议通过了《关于变更经营范围、增加董事会成员人数并修订<公司章 程>的议案》。具体内容见公司在中国证监会指定信息披露媒体巨潮资讯网 （http://www.cninfo.com.cn）披露的《第七届董事会第九次临时会议决议公告》 （公告编号：2025-53）、《关于变更经营范围、增加董事会成员人数并修订< 公司章程>以及制定、修订部分治理制度的公告》（公告编号：2025-55）、《2025 年第二次临时股东会决议公告》（公告编号：2025-58）。 近日，公司已办理完成工商变更登记及《公司章程》备案手续，并取得了由 湖北省市场监督管理局换发的《营业执照》，具体情况如下： 一、本次经营范围变更情况 ...